

# Alexander Kuo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6753263/publications.pdf>

Version: 2024-02-01

15  
papers

1,922  
citations

623734

14  
h-index

996975

15  
g-index

15  
all docs

15  
docs citations

15  
times ranked

2776  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. <i>Gastroenterology</i> , 2015, 149, 649-659.	1.3	725
2	Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study. <i>Gastroenterology</i> , 2015, 148, 100-107.e1.	1.3	307
3	Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. <i>Gastroenterology</i> , 2016, 151, 1131-1140.e5.	1.3	199
4	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , 2016, 150, 419-429.	1.3	166
5	Extended Criteria Donors in Liver Transplantation. <i>Clinics in Liver Disease</i> , 2017, 21, 289-301.	2.1	128
6	Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. <i>Liver Transplantation</i> , 2016, 22, 24-33.	2.4	100
7	Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. <i>Gut</i> , 2017, 66, 1844-1852.	12.1	69
8	Chronic Hepatitis B Infection. <i>Clinics in Liver Disease</i> , 2012, 16, 347-369.	2.1	54
9	Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 776-783.	5.8	45
10	Intravascular Ultrasound in the Creation of Transhepatic Portosystemic Shunts Reduces Needle Passes, Radiation Dose, and Procedure Time: A Retrospective Study of a Single-Institution Experience. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1148-1153.	0.5	44
11	Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. <i>Liver Transplantation</i> , 2008, 14, 1491-1497.	2.4	28
12	Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1811-1819.e4.	4.4	20
13	Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. <i>Scientific Reports</i> , 2018, 8, 3199.	3.3	18
14	Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1378-1383.	1.6	14
15	Is recurrent hepatitis C worse with living donors?. <i>Current Opinion in Organ Transplantation</i> , 2009, 14, 240-244.	1.6	5